## PDA Europe Virtual Training Course Test Methods for Pre-Filled Syringe Systems

Day 2: 11 September 2020; 2pm – 4pm CEST



Horst Koller, CEO, HK Packaging Consulting GmbH







### Agenda

- TM for final drug product filled syringes
- PFS combined with devices





ISO 11040-8

**Prefilled Syringes** 

Part 8: Requirements and tests methods for finished prefilled syringes

(TC 76)







ISO 11040-8 Prefilled Syringes

#### System characterization

Barrel (ISO 11040-4 or 11040-6 shall apply)



**Plunger stoppers** (ISO 11040-5 shall apply; talks about laminated plungers in view of plunger setting)



Additional components (plunger rod, finger flange extension, hypodermic needle, filter tubing etc)





ISO 11040-8 Prefilled Syringes

Physical system characterization (\* TM referenced to 11040-4

Annexes) Break loose and extrusion forces\* (E.1.) Burst resistance\* (G.2.) Break resistance \* (C.1. / C.2.) Closure system forces and torques\* (G.3. / G.6.) Connectivity with fluid path connectors (80369-1) Residual volume (ISO 7886-1) Needle penetration force\* (F.) Needle pull-out force\* (G.1) Anti-needlestick requirements (ISO 23908) Liquid leakage (beyond plunger ISO 7886-1) Markings (ISO 7886-1)





ISO 11040-8 Prefilled Syringes

#### **Pharmaceutical requirements**

**Drug – container interaction** (extractables / leachables / compatibility / shear forces ...)

**Biological requirements** (ISO 10993-1)

**Container closure integrity** (physical / microbiological)


**Deliverable volume** (as per IFU)

Particulates (visible and sub-visible) (applicable pharmacopeia)






#### Breakloose and Extrusion Forces TM



Breakloose force is (usually) time dependent










#### **Burst Resistance TM**











### Connectivity with Fluid path connectors

Luer connector leakage method ISO 11040 – 4; (TM = Annex G) Connectivity following ISO 80369-1

#### **Issues**?

ISO 11040-4 compliant PFS in combination with a needleless luer activated devices (NLAD's)  $\rightarrow$  ISO 80369-7 Device (Thread)




















http://www.fda.gov/Drugs/DrugSafety/ucm254215.htm

pda.org



### Connectivity with Fluid path connectors










#### **Residual Volume TM**

Determine the residual volume with drug product filled syringe as designed for the intended use (needle, environmental conditions etc.)

Follow ISO 11040 – 4; 6.5.1.3 applies (reference to ISO 7886-1; Annex C and ISO 11040-5)










#### Anti-needlestick requirements

Determine the anti-needle stick prevention features

Follow ISO 23908 Testing activation of sharp injury protection feature Challenge the device in safe mode










### Liquid leakage beyond plunger










### Markings

Examples of scales and the numbering of graduation lines are shown in Figure 2.



#### 9.2 Numbering of scales

**9.2.1** Graduation lines shall be numbered at least at the volume increments given in <u>Table 1</u>. In addition, the line denoting the nominal capacity or the lines denoting the nominal capacity and the total graduated capacity, if these differ, shall be numbered.

Examples of scale numbering are shown in Figure 2.

**9.2.2** When the syringe is held vertically with the conical tip uppermost and with the scale to the front, the numbers shall appear vertical on the scale and be approximately centred on the graduation lines to which they relate. The numbers shall be close to, but shall not touch, the ends of the graduation lines to which they relate.






### **Drug-** Container interaction

The content of the prefilled syringe shall meet the specified quality attributes throughout the shelf life when transported and stored according to the manufacturer's instructions. The impact of components (e.g. needle, tubing) on the content at the time of use shall be considered.

The following aspects shall be considered but might not be all inclusive:

- extractables/leachables, e.g residuals from forming, moulding, assembly process, gluing, sterilization process, rubber ingredients, impurities and degradation products, free silicone, as well as from labels;
- compatibility, e.g. loss of potency of the drug, adsorption, degradation of the drug, change of stability indicating parameters;
- effect of shear forces during delivery on the drug quality.








SCIENCE^ Regulation

#### **Biological requirements**

Biological hazard assessment shall be performed for the finished prefilled syringe following, e.g. ISO 10993-1.

The container closure system shall maintain sterility, achieved either by aseptic processing or by terminal sterilization, throughout its shelf life including transportation.

Endotoxin levels are specified in pharmacopoeial requirements.



pda.org



#### **Biological requirements**

Medical device categorization by			Endpoints of biological evaluation														
Nature of	body contact	Contact duration															
		A – limited (≤24 h)	Physical			Irrita tion or	Material	Acute	Sub	Sub	Chr	Impla nta	Hem	Gen	Car	Repro ductive/	
Category	Contact	B - prolonged (>24 h to 30 d) C - Long term (>30 d)	and/or chemical informa- tion	Cyto toxi city	Sens itiz ation	intra cuta neous reac tivity	media ted pyro geni cityª	syste mic toxi city <sup>b</sup>	acu te toxi city <sup>b</sup>	chro nic toxi city <sup>b</sup>	onic toxi city <sup>b</sup>	tion ef- fects- b,c	oco mpa tibil ity	otox ici- tyd	cin oge nic ityd	develop mental toxici- ty <sup>d,e</sup>	Deg rada tion <sup>f</sup>
		A	Xg	Eh	E	E											
	Intact skin	В	Х	E	E	Е											
		С	Х	E	E	Е											
Surface medical		А	х	E	E	Е											
device	Mucosal membrane	В	х	E	E	Е		Е	Е			E					
		С	Х	E	E	Е		Е	Е	Е	E	E		Е			
	Breached or	А	Х	E	E	Е	E	E									
	compromised	В	Х	E	Е	Е	E	E	Е			E					
	surface	С	Х	E	E	Е	Е	Е	E	Е	E	E		E	E		

#### Table A.1 — Endpoints to be addressed in a biological risk assessment







Check the integrity of the final PFS system (sterility over shelf-life including transportation)

Follow principles described in <USP 1207>

Validate a suitable physical, chemical container closure integrity test method

**Deterministic Methods:** 

- Head space
- High voltage leakage
- Tracer gas detection
- Pressure decay
- Vacuum decay
- Etc

- Package Integrity and Test Method Selection (1207.1)
- Package Integrity Leak Test Technologies ( 1207.2 )
- Package Seal Quality Test Methods ( 1207.3 )

#### **Probabilistic Method:**

- Microbial Challenge
- Bubble emission
- Etc





18



#### **Head Space**










High Voltage Leakage











#### **Tracer Gas**



**Schematics of** 

**Test Concepts** 

#### Plunger Tightness



#### **Closure Tightness**





#### Deliverable volume / Extractable volume

Check the deliverable volume of the final drug product filled syringe as designed for the intended use.

#### Follow instructions of use and determine dose.

#### **EP 2.9.17 Extractable Volume of parenteral preparations**

Compliance with the requirements for extractable volume is assured by filling with a volume in slight excess of the nominal volume to be withdrawn. The excess volume is determined by the characteristics of the product.

#### CARTRIDGES AND PREFILLED SYRINGES

Select one container if the nominal volume is 10 ml or more, 3 containers if the nominal volume is more than 3 ml and less than 10 ml, or 5 containers if the nominal volume is 3 ml or less. If necessary, fit the containers with the accessories required for their use (needle, piston, syringe) and transfer the entire contents of each container without emptying the needle into a dry tared beaker by slowly and constantly depressing the piston. Determine the volume in millilitres calculated as the mass in grams divided by the density.

The volume measured for each of the containers is not less than the nominal volume.





### Particulates (visible and sub-visible)

USP <790> Visible particle in injections


- no Q
- Ilumination intensity 2000 3750 lux
- 5s each against white and black background



- Light obscuration
- Membrane method

USP <788> Subvisible particles ophthalmic products [10µm / 25µm / 50µm]

- Light obscuration
- Membrane method








### Coring Test Needle

Check if rubber particles are present after rubber penetration

Follow pharmacopoeia USP\* <381> ; Ph Eur\* 3.2.9 ; JP\* 7.03 ISO 8871-series (Elastomeric parts for parenterals)


Check for visible fragments; Shall be < 5 pcs (>50µm)














#### ISO 11608-1 Needle-based injection systems for medical use -Requirements and Testmethods Part 1: NIS (TC 84)

7.1	General		
7.2			
		I	
	7.2.2 Dosing	regions	
	7.2.3 Dose se	ettings	
7.3	Sampling for ot	her primary functions	15
7.4	Assessment		15
	7.4.1 Genera	1	15
	7.4.2 Determ	ination of dose accuracy limits	
		ination of last-dose error and last-dose accuracy limits (system	
	designa	ations A and C)	17
	7.4.4 Calcula	tion of dose delivery efficiency (system designations B1 and D1,	
		led)	
	7.4.5 Accepta	ance criteria	








#### ISO 11608-1 Needle-based injection systems for medical use -Requirements and Testmethods Part 1: NIS (TC 84)

#### Table 1 — System designations

	Multi-dose container	Single-dose container
NIS with replaceable container	А	B1
	Each container holds multiple doses, the size of which may be fixed or variable (set by the user)	Each container holds a single dose, and the entire deliverable volume is expelled
		B2
		Each container holds a single dose, and a portion of the deliverable volume is expelled
NIS with non-replaceable contain-	С	D1
er which is integrated, or user assembled	Each container holds multiple doses, the size of which may be fixed or variable (set by the user)	Each container holds a single dose, and the entire deliverable volume is expelled
		D2
		Each container holds a single dose, and a portion of the deliverable volume is expelled









#### ISO 11608-1 Needle-based injection systems for medical use -Requirements and Testmethods Part 1: NIS (TC 84)

De la companya de la	System designation						
Dose accuracy matrix	А	B1	B2	С	D1	D2	
Determine doses needed	<u>7.2.3.1</u>	7.2.4	7.2.4	<u>7.2.3.1</u>	7.2.4	7.2.4	
Determine accuracy limits	<u>7.4.2.1</u>	<u>7.4.2.2</u>	<u>7.4.2.1</u>	<u>7.4.2.1</u>	<u>7.4.2.2</u>	7.4.2.1	
Determine last-dose accuracy limits (variable dose only)	<u>7.4.3</u>	N/A	N/A	<u>7.4.3</u>	N/A	N/A	
Calculate last-dose error (variable dose only)	<u>7.4.3</u>	N/A	N/A	<u>7.4.3</u>	N/A	N/A	
Calculate dose delivery efficiency (user-filled only)	N/A	<u>7.4.4</u>	N/A	N/A	<u>7.4.4</u>	N/A	
Calculate tolerance intervals	7.4.5	7.4.5	7.4.5	7.4.5	7.4.5	7.4.5	



Refer to  $\underline{Annex F}$  for a detailed discussion of sampling plans for both variable and attribute data.







### Video








ISO 11608-3 Needle-based injection systems for medical use -Requirements and Testmethods Part 3: NIS containers and integrated fluid path (TC 84)

# Prefilled Syringes are described in the ISO 11040-4 series but PFS out of 11040-8 are included when used with a NIS.


Specific requirements for NIS primary container closure system components are:

- a) glass syringes (including integrated needles) shall comply with applicable clauses of ISO 11040-4 and ISO 11040-8;
- b) plastic syringes (including integrated needles) shall comply with applicable clauses of ISO 11040-6 and ISO 11040-8;
- c) syringe plunger stoppers shall comply with applicable clauses of ISO 11040-5;
















#### ISO 11608-3 Needle-based injection systems for medical use -Requirements and Testmethods Part 3: NIS containers and integrated fluid path (TC 84)

#### 5.3 Sub-visible particulates

Prepare a test sample by filling or flushing the reservoir and/or integrated fluid path of 10 NISs with particle-free water as defined by pharmacopeia (using the filling device and/or mechanism specified in the instructions for use) into a container rinsed with particle-free water. Prepare a control sample (using the same filling device and/or mechanism specified in the instructions for use) to expel particle-free water into an appropriately cleaned container. Enumerate the sub-visible particulate matter content of the reservoir and/or integrated fluid path in accordance with applicable pharmacopeia. The number of particulates is the difference between the test samples and control.

#### 5.4 Visible particulates

Prepare a test sample by filling or flushing the reservoir and/or integrated fluid path of 10 NISs with particle-free water as defined by pharmacopeia (using the filling device and/or mechanism specified in the instructions for use) into a container rinsed with particle-free water. Prepare a control sample (using the same filling device and/or mechanism specified in the instructions for use) to expel particle-free water into an appropriately cleaned container. The test sample shall be visually inspected for the presence of visible particulates (> 150  $\mu$ m in diameter) in the test sample as compared to the control.








ISO 11608-3 Needle-based injection systems for medical use -**Requirements and Testmethods** Part 3: NIS containers and integrated fluid path (TC 84)

> Annex B (informative)

Historical references to ISO 11608-3:2012, Pen-injector cartridges dimensions and test methods (Clauses 4 and 5)



1

5





#### ISO 11608-3 Needle-based injection systems for medical use -**Requirements and Testmethods** Part 3: NIS containers and integrated fluid path

#### **(TC 84)**

**Requirements (historical 11608-3:2012)** 4

#### 4.3 Plunger force (cartridge only)

The initiating force for cartridges shall not exceed 15 N, when tested in accordance with the test method given in <u>5.4</u>.


The sustaining force for cartridges shall not exceed 10 N, when tested in accordance with the test method given in 5.4.

#### 5 Test methods (historical 11608-3:2012)

#### 5.4 Plunger forces

Measurements shall be made at a test speed of 50 mm/min with test cartridges that are open to the atmosphere (i.e. no septum present, fluid to be removed immediately prior to testing), so that only the plunger friction is measured. The initiating force is the peak force seen at the start of the plunger movement. The maximum sustaining force is measured over the measurement zone, which comprises not less than 75 % of cartridge deliverable volume.





Key

1 2

3

4

5

Disc

Cap

Label



#### ISO 11608-5 Needle-based injection systems for medical use -**Requirements and Testmethods** "Loaded" Spring Part 5: Automated Functions (TC 84) Requirements 4 General requirements . 4 Medication 4.1 Medicinal product preparation 4.2 Needle preparation 4.3 Needle hiding 4.4 4.5 Priming ..... Dose setting 4.6 Needle insertion 4.7 Injection depth control 4.8 Needle 4.9 Dose delivery Device function information 4.10 Needle retraction 4.11 4.11.1 Completion of dose delivery 4.11.2 Needle retraction distance 4.11.3 Communication of completion 4.12 Disabling the NIS-AUTO 4.13 4.13.1 General 4.13.2 Needle shielding before injection 4.13.3 Needle shielding after injection 7 4.14 Needle removal from the NIS-AUTO








#### ISO 11608-5 Needle-based injection systems for medical use -Requirements and Testmethods "Lo Part 5: Automated Functions Spr (TC 84) 5 Test methods 8

5.1	General	
5.2	Test conditions	
5.3	Actuation	(
5.4	Medicinal product preparation	
5.5	Needle inspection	
5.6	Needle hiding	Ģ
5.7	Priming	Ģ
5.8	Needle extension	
5.9	Injection time	
5.10	Dose accuracy	
5.11	Retracted position	
5.12	Disabling the NIS-AUTO	
5.13	Needle shielding	
	5.13.1 Needle shielding before and after injection	
	5.13.2 Needle shielding after free fall	







### Video







### Acknowledgements Mr. Erik Berndt – Zwick / Roell, Germany







# Thank You !

# **Q&A Session**



pda.org